Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.32, beating the estimate of USD -0.345.

EBIT: As of FY2026 Q2, the actual value is USD -20.17 M.

Research and Development (R&D) Expenses

Research and development expenses were $16.4 million for the quarter ended June 30, 2026, compared to $15.7 million for the same period in 2025. For the six months ended June 30, 2026, R&D expenses were $30.8 million, a slight decrease from $31.1 million for the six months ended June 30, 2025.

General and Administrative (G&A) Expenses

General and administrative expenses were $5.8 million for the quarter ended June 30, 2026, consistent with $5.8 million for the quarter ended June 30, 2025. For the six months ended June 30, 2026, G&A expenses were $11.1 million, compared to $10.9 million for the six months ended June 30, 2025.

Total Operating Expenses

Total operating expenses for the second quarter of 2026 were $22.2 million, up from $21.6 million in the prior year’s second quarter. For the six months ended June 30, 2026, total operating expenses were $41.9 million, a slight decrease from $42.0 million for the same period in 2025.

Loss from Operations

Loss from operations was - $22.2 million for the quarter ended June 30, 2026, compared to - $21.6 million for the same period in 2025. For the six months ended June 30, 2026, loss from operations was - $41.9 million, compared to - $42.0 million for the six months ended June 30, 2025.

Other Income, Net

Other income, net, was $2.0 million for the second quarter of 2026, down from $2.5 million in the second quarter of 2025. For the six months ended June 30, 2026, other income, net, was $4.1 million, compared to $5.2 million for the same period in 2025.

Net Loss

Net loss for the quarter ended June 30, 2026, was - $20.2 million, compared to a net loss of - $19.1 million for the same period in 2025. For the six months ended June 30, 2026, net loss was - $37.8 million, compared to - $36.8 million for the six months ended June 30, 2025.

Cash Position

Cash, cash equivalents, and investment securities totaled $207.4 million as of June 30, 2026, a decrease from $219.8 million as of December 31, 2025.

Assets

Total current assets were $212.0 million as of June 30, 2026, down from $223.8 million as of December 31, 2025. Property and equipment, net, was $0.7 million as of June 30, 2026, compared to $1.0 million as of December 31, 2025. Right-of-use asset increased to $2.4 million as of June 30, 2026, from $1.4 million as of December 31, 2025. Total assets were $215.1 million as of June 30, 2026, compared to $226.2 million as of December 31, 2025.

Liabilities and Stockholders’ Equity

Total current liabilities were $11.2 million as of June 30, 2026, a decrease from $13.1 million as of December 31, 2025. Accounts payable increased to $3.1 million as of June 30, 2026, from $2.3 million as of December 31, 2025, while accrued expenses and other current liabilities decreased to $8.1 million from $10.7 million over the same period. Total liabilities were $13.3 million as of June 30, 2026, compared to $13.7 million as of December 31, 2025. Total stockholders’ equity was $201.9 million as of June 30, 2026, down from $212.5 million as of December 31, 2025.

Outlook / Guidance

Design Therapeutics, Inc. expects to provide an update on its registrational plans for the RESTORE-FA trial in the fourth quarter of 2026 and anticipates data following 12 weeks of treatment for this trial in the first quarter of 2027. The company also expects to report data from its Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 patients in 2027. Data from the DT-168 Phase 2 biomarker trial for Fuchs Endothelial Corneal Dystrophy is also expected in 2027, due to supply delays.